BR9713521A - - Google Patents

Info

Publication number
BR9713521A
BR9713521A BR9713521A BR9713521A BR9713521A BR 9713521 A BR9713521 A BR 9713521A BR 9713521 A BR9713521 A BR 9713521A BR 9713521 A BR9713521 A BR 9713521A BR 9713521 A BR9713521 A BR 9713521A
Authority
BR
Brazil
Prior art keywords
sugar
antibodies
amino
polyclonals
monoclonal
Prior art date
Application number
BR9713521A
Other languages
English (en)
Inventor
Gerhard Winter
Christian Klessen
Heinrich Woog
Georg Kallmeyer
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8223412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9713521(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of BR9713521A publication Critical patent/BR9713521A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

POLICLONAIS"<D>. A invenção se refere a preparações farmacêuticas liofilizadas de anticorpos monoclonais ou policlonais, que contêm um açúcar ou um am processo para a produção desses liofilizados estáveis, bem como o uso de um açúcar ou amino-açúcar, um aminoácido e um tensoativo como estabilizadoro anticorpos.
BR9713521A 1996-11-19 1997-11-19 BR9713521A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96118489A EP0852951A1 (de) 1996-11-19 1996-11-19 Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
PCT/EP1997/006452 WO1998022136A2 (de) 1996-11-19 1997-11-19 Stabile lyophilisierte pharmazeutische zubereitungen von mono- oder polyklonalen antikörpern

Publications (1)

Publication Number Publication Date
BR9713521A true BR9713521A (pt) 2000-03-21

Family

ID=8223412

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713521A BR9713521A (pt) 1996-11-19 1997-11-19

Country Status (19)

Country Link
US (2) US8758747B2 (pt)
EP (2) EP0852951A1 (pt)
JP (2) JP4536829B2 (pt)
KR (1) KR100514207B1 (pt)
CN (1) CN1155408C (pt)
AR (2) AR012540A1 (pt)
AT (1) ATE276762T1 (pt)
AU (2) AU735411C (pt)
BR (1) BR9713521A (pt)
CA (1) CA2272245C (pt)
DE (1) DE59711959D1 (pt)
DK (1) DK0941121T3 (pt)
ES (1) ES2227727T3 (pt)
ID (1) ID19029A (pt)
PT (1) PT941121E (pt)
TR (1) TR199901696T2 (pt)
TW (1) TW520291B (pt)
WO (1) WO1998022136A2 (pt)
ZA (1) ZA9710409B (pt)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
PT917879E (pt) * 1997-11-22 2002-12-31 Roche Diagnostics Gmbh Processo melhorado para estabilizacao de proteinas
WO2000066160A1 (fr) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
WO2002013860A1 (fr) * 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees contenant un anticorps
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
TWI232102B (en) * 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection
ATE414537T1 (de) 2001-08-29 2008-12-15 Chugai Pharmaceutical Co Ltd Antikörper enthaltende stabilisierte zubereitungen
EP1441589B1 (en) * 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
JP4364645B2 (ja) * 2002-02-14 2009-11-18 中外製薬株式会社 抗体含有溶液製剤
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004028557A1 (ja) * 2002-09-26 2004-04-08 Shionogi & Co., Ltd. 安定化されたタンパク組成物
EP1561759B9 (en) 2002-10-11 2009-08-26 Chugai Seiyaku Kabushiki Kaisha Cell death-inducing agent
MXPA05008409A (es) 2003-02-10 2005-10-05 Elan Pharm Inc Formulacion de inmunoglobulina y metodo para la preparacion de la misma.
US8765124B2 (en) 2003-02-28 2014-07-01 Chugai Seiyaku Kabushiki Kaisha Stabilized preparation containing protein
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
EP1684719B1 (en) * 2003-11-14 2011-10-26 Baxter International Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
WO2005056603A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha 細胞死誘導剤
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
WO2005056602A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
JP4799405B2 (ja) * 2004-04-09 2011-10-26 中外製薬株式会社 細胞死誘導剤
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
KR20180091967A (ko) 2004-07-22 2018-08-16 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
JPWO2006030730A1 (ja) * 2004-09-15 2008-05-15 大塚製薬株式会社 経粘膜用組成物、及び経粘膜吸収の向上方法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101141981A (zh) * 2005-01-21 2008-03-12 健泰科生物技术公司 Her抗体的固定剂量给药
CN1313161C (zh) * 2005-01-27 2007-05-02 北京大学临床肿瘤学院 结直肠癌放射免疫导向手术药物及其制备方法
EP2399605A1 (en) * 2005-02-23 2011-12-28 Genentech, Inc. Extending time to disease progression or survival in cancer patients
WO2006106903A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2構造異性体
US7785595B2 (en) 2005-04-18 2010-08-31 Yeda Research And Development Company Limited Stabilized anti-hepatitis B (HBV) antibody formulations
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
WO2007092772A2 (en) * 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
JP5364382B2 (ja) 2006-02-07 2013-12-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 遊離チオール部分を有するタンパク質の安定化された組成物
AU2013224728B2 (en) * 2006-02-07 2016-10-20 Takeda Pharmaceutical Company Limited Stabilized Compositions of Proteins Having a Free Thiol Moiety
EP1987067A4 (en) * 2006-02-15 2012-01-25 Imclone Llc ANTIBODY FORMULATION
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
MX2009000487A (es) * 2006-07-13 2009-01-27 Chugai Pharmaceutical Co Ltd Inductor de muerte celular.
TW200826974A (en) * 2006-09-07 2008-07-01 Kirin Pharma Kk Stable lyophilized pharmaceutical preparation comprising antibody
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
CA2692165A1 (en) 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
KR20090056543A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 Ｂ형 간염 바이러스(ｈｂｖ) 중화 인간 항체를 포함하는약학적 제제
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
AR075715A1 (es) * 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
RU2011140498A (ru) 2009-03-06 2013-04-20 Дженентек, Инк. Препарат антител
MX2012001268A (es) 2009-07-28 2012-09-12 Shire Human Genetic Therapies Composiciones y metodos para tratar enfermedad de gaucher.
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011021308A1 (ja) 2009-08-21 2011-02-24 Ｎｅｃソフト株式会社 げっ歯類由来ＩｇＧ抗体に結合性を有する核酸分子、結合剤、検出試薬および検出キット
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
ES2716088T3 (es) 2010-02-04 2019-06-10 Csl Behring Ag Preparado de inmunoglobulina
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
EP3345615B1 (en) 2010-03-01 2019-10-16 Bayer Healthcare LLC Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
SG186421A1 (en) * 2010-07-02 2013-01-30 Medimmune Llc Antibody formulations
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
ES2639617T3 (es) 2010-10-12 2017-10-27 Merz Pharma Gmbh & Co. Kgaa Formulación adecuada para estabilizar proteínas, que carece de excipientes de mamíferos
TWI616204B (zh) 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
MX344727B (es) 2010-11-11 2017-01-05 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
KR20200133826A (ko) 2011-01-28 2020-11-30 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 특정 대상자 그룹의 치료 방법에 이용하기 위한 ｐｃｓｋ9에 대한 인간 항체
JP5458188B2 (ja) 2011-02-17 2014-04-02 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤
LT2691112T (lt) * 2011-03-31 2018-07-25 Merck Sharp & Dohme Corp. Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP2704751B1 (en) * 2011-05-02 2019-04-17 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA028278B1 (ru) 2011-09-16 2017-10-31 Ридженерон Фармасьютикалз, Инк. СПОСОБЫ СНИЖЕНИЯ УРОВНЕЙ ЛИПОПРОТЕИНА(а) ПОСРЕДСТВОМ ВВЕДЕНИЯ ИНГИБИТОРА ПРОПРОТЕИНКОНВЕРТАЗЫ СУБТИЛИЗИН/КЕКСИН-9 (PCSK9)
CN104334189A (zh) 2011-10-14 2015-02-04 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
JP6113176B2 (ja) 2011-10-18 2017-04-12 コヒラス・バイオサイエンシズ・インコーポレイテッド キシリトールによって安定化されたエタネルセプト製剤
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
KR102196009B1 (ko) 2011-10-25 2021-01-04 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
CN104169299B (zh) 2012-01-23 2018-06-05 瑞泽恩制药公司 含抗Ang-2 抗体的稳定化制剂
CA2865614A1 (en) 2012-03-02 2013-09-06 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type iii gaucher disease
MX363700B (es) * 2012-03-07 2019-03-29 Cadila Healthcare Ltd Formulaciones farmaceuticas de anticuerpos tnf-alfa.
AR092325A1 (es) 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
EA029193B1 (ru) 2012-07-09 2018-02-28 Кохерус Байосайенсис, Инк. Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
RS60226B1 (sr) 2012-09-07 2020-06-30 Coherus Biosciences Inc Stabilne vodene formulacije adalimumaba
IN2015KN00452A (pt) 2012-09-11 2015-07-17 Coherus Biosciences Inc
CN102961745B (zh) * 2012-09-27 2015-02-18 苏州康聚生物科技有限公司 抗体组合物制剂及其应用
NZ751877A (en) 2013-04-16 2020-04-24 Genentech Inc Pertuzumab variants and evaluation thereof
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EA201592267A1 (ru) 2013-06-07 2016-04-29 Ридженерон Фармасьютикалз, Инк. Способы ингибирования атеросклероза посредством введения ингибитора pcsk9
CN118105481A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
CA2946860A1 (en) 2014-04-25 2015-10-29 Genentech, Inc. Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
IS3008B (is) * 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
CN107206068A (zh) 2014-07-16 2017-09-26 赛诺菲生物技术公司 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
NZ731518A (en) * 2014-12-17 2019-03-29 Pfizer Formulations of a pi3k/mtor-inhibitor for intravenous administration
BR112017022101A2 (pt) 2015-04-14 2018-07-31 Chugai Seiyaku Kabushiki Kaisha composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo
ES2882106T3 (es) 2015-04-21 2021-12-01 Staidson Beijing Biopharmaceuticals Co Ltd Composición de factor de crecimiento nervioso y polvo para inyección
EP3302551B1 (en) 2015-05-30 2024-06-26 F. Hoffmann-La Roche AG Methods of treating her2-positive previously untreated metastatic breast cancer
WO2017031151A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
TWI787161B (zh) * 2015-12-18 2022-12-21 日商安斯泰來製藥股份有限公司 含有抗人類ｔｓｌｐ受體抗體之醫藥組成物
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
CN109803640B (zh) * 2016-08-10 2022-01-04 赛特瑞恩股份有限公司 稳定的液体抗流感病毒抗体医药调配物
EA201990900A1 (ru) 2016-10-07 2019-07-31 Ридженерон Фармасьютикалз, Инк. Стабильный при комнатной температуре лиофилизированный белок
EP3528787A4 (en) 2016-10-21 2020-05-06 Amgen Inc. PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION
CA3047349C (en) 2017-01-17 2020-09-22 Genentech, Inc. Subcutaneous her2 antibody formulations
RS65204B1 (sr) 2017-03-02 2024-03-29 Genentech Inc Adjuvansni tretman her2-pozitivnog raka dojke
EP3675815A1 (en) * 2017-08-31 2020-07-08 Xellia Pharmaceuticals ApS Daptomycin formulations
US20220080376A1 (en) 2019-02-15 2022-03-17 The Regents Of The University Of California Methods for converting colloidal systems to resuspendable/redispersable powders that preserve the original properties of the colloids
WO2021100794A1 (ja) * 2019-11-20 2021-05-27 中外製薬株式会社 抗体含有製剤

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016043A (en) * 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
JPS56113713A (en) 1980-02-14 1981-09-07 Chemo Sero Therapeut Res Inst Preparation of immunoglobulin with high content of monomer
US4439421A (en) 1982-08-30 1984-03-27 Baxter Travenol Laboratories, Inc. Stabilized gamma globulin concentrate
JPS60146833A (ja) 1984-01-10 1985-08-02 Green Cross Corp:The モノクロ−ナル抗体製剤
US4650772A (en) 1984-08-09 1987-03-17 Abbott Laboratories Monoclonal antibody stabilization
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
JPH0825902B2 (ja) 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPS6388197A (ja) 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
DE3877015T2 (de) 1987-02-20 1993-05-06 Akzo Nv Antikoerper enthaltende stabilisierte waesserige zusammensetzung.
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
ATE82136T1 (de) 1987-08-10 1992-11-15 Miles Inc Gereinigtes igm.
JPS6475433A (en) 1987-09-16 1989-03-22 Teijin Ltd Remedy for herpes simplex virus infection
ATE88352T1 (de) 1988-02-26 1993-05-15 Genentech Inc Humanes relaxinpraeparat.
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH03504499A (ja) 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
JPH03504605A (ja) 1988-05-27 1991-10-09 セントカー・インコーポレーテツド 抗体産生物の凍結乾燥した配合物
DE3825429C2 (de) 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US5468468A (en) * 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
DE3927111C3 (de) * 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
GB9015824D0 (en) 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
JP2966592B2 (ja) 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
GB9120304D0 (en) * 1991-09-24 1991-11-06 Erba Carlo Spa Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
AU684455B2 (en) 1992-11-06 1997-12-18 Sandoz Ltd. Production of human monoclonal antibodies active against hepatitis B surface antigen
JPH08503617A (ja) 1992-12-01 1996-04-23 プロテイン デザイン ラブズ、インコーポレーテッド Ｌ−セレクチンに反応性のヒト化抗体
DE4242863A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
JP3537440B2 (ja) 1993-12-17 2004-06-14 持田製薬株式会社 可溶性トロンボモジュリンを長期保存安定化させる方法
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
ES2197210T3 (es) 1994-11-30 2004-01-01 Ajinomoto Co., Inc. Agente antitrombotico y anticuerpos monoclonales contra el factor von willebrand.
CA2210620C (en) 1995-01-18 2004-06-22 Boehringer Mannheim Gmbh Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen
DE19508192A1 (de) * 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP1516628B1 (en) * 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern

Also Published As

Publication number Publication date
JP2001503781A (ja) 2001-03-21
AU772940B2 (en) 2004-05-13
KR100514207B1 (ko) 2005-09-13
CN1244805A (zh) 2000-02-16
DK0941121T3 (da) 2005-01-31
ZA9710409B (en) 1999-05-19
US8758747B2 (en) 2014-06-24
AU7824201A (en) 2001-11-22
DE59711959D1 (de) 2004-10-28
PT941121E (pt) 2005-01-31
CA2272245C (en) 2013-09-10
JP2009046494A (ja) 2009-03-05
JP4536829B2 (ja) 2010-09-01
EP0941121B1 (de) 2004-09-22
AR074958A2 (es) 2011-02-23
CN1155408C (zh) 2004-06-30
JP5153532B2 (ja) 2013-02-27
EP0852951A1 (de) 1998-07-15
WO1998022136A2 (de) 1998-05-28
AU5484198A (en) 1998-06-10
CA2272245A1 (en) 1998-05-28
TR199901696T2 (xx) 1999-09-21
US20080286280A1 (en) 2008-11-20
WO1998022136A3 (de) 1998-08-20
AU735411C (en) 2004-08-05
ID19029A (id) 1998-06-04
ATE276762T1 (de) 2004-10-15
US20140248274A1 (en) 2014-09-04
TW520291B (en) 2003-02-11
AU735411B2 (en) 2001-07-05
ES2227727T3 (es) 2005-04-01
KR20000053328A (ko) 2000-08-25
AR012540A1 (es) 2000-11-08
EP0941121A2 (de) 1999-09-15

Similar Documents

Publication Publication Date Title
BR9713521A (pt)
BR0114475A (pt) Célula para a produção de composição de anticorpo
NO2017028I2 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
ES2190087T3 (es) Formulacion estabilizada de un anticuerpo.
ATE316982T1 (de) Mehrere zytokin-antikörper komplexen
CA2294078A1 (fr) Procede de dosage specifique du c-peptide
FR12C0004I2 (fr) Anticorps contre l&#39;antigene ctla-4 humain et utilisation
DE60037450D1 (de) Funf-helix protein
WO2004019861A3 (en) Stable ph optimized formulation of a modified antibody
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
DK1111385T3 (da) Enzym-protein-kompleks
WO1998039450A3 (de) Oberflächenprotein (spsa-protein) von streptococcus pneumoniae deletierte abkömmlinge, expressionssssystem für diese proteine und vaccine mit den proteinen
BR0015287A (pt) Moléculas recombinantes de fusão
DE69938725D1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
ATE408631T1 (de) Chimäres protein welches eine intramolekulare chaperon-ähnliche sequenz enthält und dessen anwendung zur insulinproduktion
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
CA2137280A1 (fr) Clonage du gene codant pour la proteine gp28.5 de toxoplasma gondii; fragments peptidiques de cette proteine et leurs applications
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
DE60236853D1 (de) Pharmazeutische zusammensetzung aus f(ab) 2- fragmenten von antikörpern und verfahren zu ihrer herstellung
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
DE69840628D1 (de) Nicht-anaphylaktische allergenarten und ihre verwendung
BRPI9715268B8 (pt) preparações farmacêuticas liofilizadas estáveis de anticorpos monoclonais ou policlonais, bem como processo para sua produção
DE60042273D1 (de) Antitumorantikörper, proteine und deren verwendung

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: CONCLUI-SE QUE A MATERIA REQUERIDA NAO ATENDE AOS REQUISITOS DE PATENTEABILIDADE DE ACORDO COM O SARTIGOS 8O C/C 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]